Cite
Gordon JA, Buonerba C, Pond G, et al. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget. 2018;9(28):19861-19873doi: 10.18632/oncotarget.24888.
Gordon, J. A., Buonerba, C., Pond, G., Crona, D., Gillessen, S., Lucarelli, G., Rossetti, S., Dorff, T., Artale, S., Locke, J. A., Bosso, D., Milowsky, M. I., Witek, M. S., Battaglia, M., Pignata, S., Cherhroudi, C., Cox, M. E., De Placido, P., Ribera, D., Omlin, A., Buonocore, G., Chi, K., Kollmannsberger, C., Khalaf, D., Facchini, G., Sonpavde, G., De Placido, S., Eigl, B. J., & Di Lorenzo, G. (2018). Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget, 9(28), 19861-19873. https://doi.org/10.18632/oncotarget.24888
Gordon, Jacob A, et al. "Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study." Oncotarget vol. 9,28 (2018): 19861-19873. doi: https://doi.org/10.18632/oncotarget.24888
Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget. 2018 Apr 13;9(28):19861-19873. doi: 10.18632/oncotarget.24888. eCollection 2018 Apr 13. PMID: 29731989; PMCID: PMC5929432.
Copy
Download .nbib